In This Article:
Company Announcement
COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.
The following transactions were executed under the program from May 12 to May 16, 2025:
|
| Trading Platform | No. of shares | Average price (DKK) | Total value (DKK) |
| Accumulated through last announcement |
| 1,670,570 |
| 2,167,424,708.55 |
| May 12, 2025 | XCSE | 45,452 | 1,273.20 | 57,869,559.12 |
|
| BCXE | 25,756 | 1,273.43 | 32,798,537.77 |
|
| AQEU | 4,802 | 1269.90 | 6,098,083.33 |
|
| TQEX | 4,770 | 1,269.42 | 6,055,150.10 |
|
| Total | 80,780 |
| 102,821,330.32 |
| May 13, 2025 | XCSE | 36,856 | 1,301.93 | 47,984,042.65 |
|
| BCXE | 22,268 | 1,305.23 | 29,064,854.96 |
|
| AQEU |
|
|
|
|
| TQEX |
|
|
|
|
| Total | 59,124 |
| 77,048,897.61 |
| May 14, 2025 | XCSE | 29,137 | 1,301.02 | 37,907,802.26 |
|
| BCXE | 27,818 | 1,300.72 | 36,183,370.54 |
|
| AQEU | 3,750 | 1,300.80 | 4,877,986.88 |
|
| TQEX | 5,471 | 1,300.82 | 7,116,803.73 |
|
| Total | 66,176 |
| 86,085,963.41 |
| May 15, 2025 | XCSE | 25,356 | 1,299.36 | 32,946,478.34 |
|
| BCXE | 17,633 | 1,299.36 | 22,911,671.31 |
|
| AQEU | 1,100 | 1,299.31 | 1,429,241.99 |
|
| TQEX | 3,922 | 1,298.57 | 5,092,977.03 |
|
| Total | 48,011 |
| 62,380,368.67 |
| May 16, 2025 | XCSE | 38,051 | 1,322.58 | 50,325,426.82 |
|
| BCXE | 14,938 | 1,322.33 | 19,753,007.37 |
|
| AQEU | 3,000 | 1,322.47 | 3,967,398.00 |
|
| TQEX | 3,000 | 1,322.41 | 3,967,221.00 |
|
| Total | 58,989 |
| 78,013,053.19 |
| Total |
| 313,080 |
| 406,349,613.20 |
| Accumulated under the program | 1,983,650 |
| 2,573,774,321.75 | |
.
Details of each transaction are included as an appendix to this announcement.
Following these transactions, Genmab holds 2,435,377 shares as treasury shares, corresponding to 3.8% of the total share capital and voting rights.
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 14 dated March 25, 2025.
About Genmab
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®.